Evidence map›Paper›PMID 40681596›Full record

ArticleScientific reports2025

Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1.

Nicole Naumann, Vito Dangelo, Johannes Lübke, Jakob Bresser, Volker Hagen, Jolanta Dengler, Georgia Metzgeroth, Sebastian Kreil, Tabea Hockenberger, Wolf-Karsten Hofmann and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nicole NaumannDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Vito DangeloDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Johannes LübkeDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Jakob BresserDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Volker HagenKlinik für Innere Medizin II, St. Johannes Hospital Dortmund, Dortmund, Germany.
Jolanta DenglerOnkologikum Stuttgart, Stuttgart, Germany.
Georgia MetzgerothDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Sebastian KreilDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Tabea HockenbergerDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Wolf-Karsten HofmannDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Alice FabariusDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Susanne SausseleDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Nicholas C P CrossFaculty of Medicine, University of Southampton, Southampton, UK.
Andreas ReiterDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Juliana SchwaabDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany. juliana.schwaab@medma.uni-heidelberg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diagnosis and treatment of chronic myeloid neoplasms with two concurrently present driver mutations is challenging. We report on 10 JAK2 V617F

Indexed as

Fusion Proteins, bcr-ablJanus Kinase 2Leukemia, Myelogenous, Chronic, BCR-ABL PositiveMyeloproliferative DisordersProto-Oncogene Proteins c-ablAdultAgedDasatinibFemaleHumansImatinib MesylateMaleMiddle AgedMutationNitrilesProtein Kinase InhibitorsABL1 protein, humanDasatinibFusion Proteins, bcr-ablImatinib MesylateJAK2 protein, humanJanus Kinase 2nilotinibNitrilesProtein Kinase InhibitorsProto-Oncogene Proteins c-ablPyrazolesPyrimidinesruxolitinib

Identifiers

PMID40681596
PMCPMC12274285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.